Barcelona is in the prime of Life Sciences. The city has consolidated itself as one of the main hubs in Europe and in the world. With more than 1,500 companies in the sector, 300,000 jobs and an ecosystem that combines universities of excellence, leading biotechnological and pharmaceutical companies, the city is among the ten most important global centers in this area.
However, competition is fierce, with multi-million dollar strategies such as LifeSci NY in New York and Saudi Arabia's biotechnology investments within the framework of Neom.
The path to here has been the result of years of successful public policies. The foundation of the ecosystem was established by Professor Andeu Mas-Colell, promoting a university and research model based on excellence. Since then, the effort of business and institutional leaders has consolidated an environment in which scientific parks, research centers and prestigious universities coexist.
Following Professor Daniel Isenberg's conceptual framework in How to Start an Entrepreneurial Revolution (Harvard Business Review, 2010), Barcelona has advanced in key aspects such as adequate public policies, entrepreneurial culture, infrastructure support, specialized financing and talent attraction. Organizations like Barcelona Global actively work to maintain and strengthen this model.
The Barcelona ecosystem
The first pillar of the ecosystem is the university sphere. Barcelona is a leader in Spain in Life Sciences thanks to universities such as UB, UPF and UAB, with leading Medicine and Biotechnology faculties and university hospitals that are among the best in the world. The training of more than 25,000 annual graduates in related disciplines, along with the rise of AI applied to biomedicine, reinforces the city's position. Private universities have also contributed with a more entrepreneurship-oriented approach, highlighting IESE, ESADE and IQS.
Secondly, the industrial sector is key. Barcelona not only has innovative startups, but also large global companies such as Grifols, Werfen, Almirall, and Ferrer, which act as growth engines. These companies collaborate closely with academia, generating an environment where research translates into applied innovation. The arrival of multinationals like AstraZeneca and Alexion, coupled with the consolidated presence of Novartis, Boehringer Ingelheim, and Roche, reinforces Barcelona as a hub for attracting investment and talent.
The third essential element is the combination of entrepreneurship, specialized financing, and technology transfer. Scientific entrepreneurs have grown by 25% in the last five years, and venture capital funds have allowed science to be transformed into industry. Public support programs like Accelera from the Barcelona City Council or those from the Institut Català de Finances (ICF) have been crucial, although the Draghi report highlights that the city remains conservative in high-risk investment.
Pending challenges
Despite the progress, Barcelona must continue working to consolidate its ecosystem. It is key to ensure more support for research centers, foster entrepreneurship at all educational levels, and unlock innovation with greater specialized investment. Attracting and retaining global talent is a priority, as is strengthening infrastructures such as science parks and early-stage financing programs for startups.
The path is set: continue scaling, promoting collaboration, attracting investment, and developing talent. Barcelona has all the ingredients to remain a global benchmark in Life Sciences. Fem que passi!